Harbor

Competitive Intelligence & Product Roadmap

Turns trial protocols and source documents into AI-built EDC workflows.

Company Overview

Harbor is an AI-native EDC that turns protocols into study builds and extracts source-document data into eCRFs. Serving customers across medtech (BioDynamik, Biolinq), reproductive genetics (NOVA Genomics), biotech (Kalevala Therapeutics), and academic health systems (University Hospitals).

Latest Intel

Zeitgeist tracks private signals to determine where the company is heading strategically.

New Intel: Harbor is centering the product on source-document extraction into EDC workflows. That changes the budget target from database software alone to study startup, site data entry, and remote monitoring spend.

May 18, 2026

Deployment Bottleneck

Confidence:

Medium

New Intel: Harbor is adding customer-facing technical deployment capacity around AI-built EDC rollout. That points to enterprise and CRO deals where validation, integrations, and site support decide whether Medidata and Veeva become exposed.

What They're Building

The company's public product roadmap & what they're committed to building.

Magic Build

Protocol PDFs are converted into a draft schedule of events, eCRFs, source documents, and database structure for clinical studies.

Magic Capture

Sites upload source documents and Harbor extracts structured fields into the EDC while keeping human review in the workflow.

Magic Monitor

Remote monitoring pairs source documents with EDC fields and adds confidence and clinical relevance scoring for review.

Validation Package

Commercial studies include 21 CFR Part 11 validation materials, audit trails, eSignatures, and role-based access controls.

Enterprise & CRO Layer

Enterprise pricing adds MSA support, SSO and SAML, CTMS and eTMF integrations, and dedicated customer success.

Founder and Key Execs

Albert Cai

Co-Founder and CEO (clinical trials and regulatory strategy at Biolinq, FDA De Novo experience)

Nathan Leung

Co-Founder and CTO (engineering at Jupiter, Google, Ramp, and Caldera)

Founder Force Multiplier

Cai brings clinical trial and regulatory operating experience from Biolinq, while Leung brings secure systems and product engineering experience from Jupiter, Google, Ramp, and Caldera. The combination fits a regulated workflow where speed only matters if the audit trail survives.

Funding History

2026 | Y Combinator Spring 2026 company
2026 | Launch YC post said Harbor was live in five clinical studies

Notable Open Roles

Forward-Deployed Engineer

This points to a hands-on enterprise rollout model where validation, integrations, and production support are core to adoption in regulated clinical trials.

Sales Development Representative

This suggests Harbor is moving from founder-led demand into repeatable outbound for clinical operations buyers at sponsors, CROs, and medtech companies.

Competitors

Medidata:

A large incumbent EDC and clinical trial platform that Harbor positions against on setup speed and AI-native data capture.

Viedoc:

An established EDC vendor in Harbor’s named legacy set, with a more traditional study-build model.

Veeva:

A broad life sciences cloud vendor whose clinical stack competes for sponsor and CRO workflows.

REDCap:

A common academic research database substitute, stronger in adoption than in AI-driven protocol-to-EDC automation.

Harbor

's Moat:

Workflow switching costs could emerge if Harbor owns protocol intent, source documents, EDC data, audit trails, and monitoring queries inside one study record.

How They're Leveraging AI

Protocol-to-EDC Study Build

Harbor uses AI to read clinical trial protocols and generate draft study structures, including schedules of events, eCRFs, source documents, and database objects. The user is the clinical operations team that otherwise spends weeks translating protocol text into EDC configuration.

Source Document Field Extraction

Harbor uses AI to extract structured clinical data from uploaded source documents into eCRFs. Sites keep their existing source workflows while the system reduces manual transcription into the EDC.

Confidence-Aware Remote Monitoring

Harbor uses AI-generated confidence and clinical relevance scoring to help monitors compare source documents against EDC fields. The system appears designed to triage review work rather than replace clinical oversight.

AI Use Overview:

Harbor applies schema-constrained document AI to clinical protocols and source files, turning unstructured trial documents into auditable EDC objects with human confirmation.

Bio, Drug Discovery, and Medical Imaging

10xScience

Turns weeks of manual protein analysis into minutes for drug development teams.

CellType

Simulates human biology with AI to predict drug effects and run virtual trials.

Google CEO Sundar Pichai highlighted their C2S-Scale 27B model for generating a novel cancer hypothesis that was later validated experimentally. CellType simulates human biology to predict drug effects using foundation models presented at ICML 2024, with all deals coming inbound from top-10 pharma. Yale professor turned down Google to build it.

Ditto Biosciences

Mines parasite genomes to discover protein therapeutics for autoimmune diseases.

Parasites evolved to suppress human immune responses over millions of years. Ditto mines their genomes for immunomodulatory proteins, and over 98% of those proteins remain uncharacterized. Three PhDs from Harvard, Berkeley, and UCSF with 40+ years of combined expertise in host-parasite biology.

Mango Medical

Automates surgical planning for orthopedic procedures from CT scans using agentic AI.

Surgical planning for shoulder replacements takes hours of manual CT scan interpretation. Mango automates it in seconds via API, already past $500K ARR before demo day, with an 8-figure LOI from a leading orthopedic company. Only company in YC W26 pursuing FDA 510(k) clearance.

Back To All Companies >